Pituitary Gland Disorders

Acromegaly & Pituitary Adenoma

Evidence-based clinical insights and management strategies by Dr. Ibrar Ahmad.

📌

Key Facts

Acromegaly is a chronic, progressive hormonal disorder caused by an overproduction of Growth Hormone (GH). It is a rare condition, typically diagnosed in middle-aged adults. If left untreated, it can lead to severe complications including cardiovascular disease, Type 2 diabetes, and sleep apnea.

🧬

Pathophysiology

Over 95% of cases are caused by a benign (noncancerous) pituitary adenoma. This tumor hypersecretes GH, which in turn triggers the liver to overproduce Insulin-like Growth Factor 1 (IGF-1). IGF-1 is the primary mediator of bone and soft tissue overgrowth throughout the body.

🌡️

Symptoms & Clinical Features

Acral overgrowth (widening of hands and feet, changing ring or shoe size).
Facial changes: Prominent brow, enlarged nose, protruding lower jaw (prognathism).
Skin changes: Oily skin, excessive sweating, and skin tags.
Carpal tunnel syndrome and peripheral neuropathy.
Macroglossia (enlarged tongue) leading to obstructive sleep apnea.
Joint pain (arthralgia) and spine curvature issues.
Cardiomegaly and hypertension.
Acromegaly & Pituitary Adenoma
Fig 1.1: Clinical visualization of endocrine pathways related to acromegaly & pituitary adenoma.
🔬

Diagnosis

Screening starts with serum IGF-1 levels (stable throughout the day). Confirmation is via an Oral Glucose Tolerance Test (OGTT), where GH levels fail to suppress below 1 mcg/L after glucose intake. A high-resolution contrast-enhanced Pituitary MRI is then performed to visualize the adenoma.

📊

Diagnostic Pathway

1
Initial Screening

Symptom review and baseline hormonal blood tests.

2
Confirmatory Testing

Advanced diagnostic protocols (e.g., OGTT, MRI, Suppression tests).

3
Personalized Plan

Tailored treatment strategy based on clinical results.

Clinical Flowchart
Fig 2.1: Specialized clinical decision matrix for acromegaly & pituitary adenoma.
💊

Treatment & Management

Transsphenoidal surgery is the first-line treatment for most patients. Medical management includes Somatostatin Analogs (Octreotide, Lanreotide) to inhibit GH secretion, Growth Hormone Receptor Antagonists (Pegvisomant) to block IGF-1 production, and Dopamine Agonists (Cabergoline). Stereotactic radiosurgery is reserved for persistent cases.

Consult with Specialist

Personalized treatment plans for your health.